A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias.
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2013
At a glance
- Drugs Bortezomib (Primary) ; Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 14 Nov 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov